Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell E Ware

Showing results (191-200 of 267) with videos related to

Pageof 27
Sort By:
Haematologica|October 26, 2019
Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohortRobert O Opoka, Heather A Hume, Teresa S Latham, et al.
The New England Journal of Medicine|December 4, 2018
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan AfricaLéon Tshilolo, George Tomlinson, Thomas N Williams, et al.
Blood|August 31, 2011
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemiaRussell E Ware, Jenny M Despotovic, Nicole A Mortier, et al.
Frontiers in Physiology|April 12, 2021
Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell AnemiaAlina Sadaf, Katie G Seu, Elizabeth Thaman, et al.
Blood|December 2, 2011
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectinJeffrey D Lebensburger, Thad Howard, Yunming Hu, et al.
American Journal of Hematology|July 18, 2013
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trialOfelia Alvarez, Nancy A Yovetich, J Paul Scott, et al.
Trials|September 22, 2023
Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC diseaseLuke R Smart, Catherine I Segbefia, Teresa S Latham, et al.
JMIR Research Protocols|June 4, 2017
Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell AnemiaNeelum D Jeste, Luisanna M Sánchez, Gabriela S Urcuyo, et al.
Journal of Pediatric Hematology/Oncology|July 26, 2018
Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell AnemiaLori E Crosby, Ashley Walton, Lisa M Shook, et al.
Blood|August 24, 2012
Impact of hydroxyurea on clinical events in the BABY HUG trialCourtney D Thornburg, Beatrice A Files, Zhaoyu Luo, et al.
Pageof 27

Showing results (191-200 of 267) with videos related to

Sort By:
Pageof 27
Haematologica|October 26, 2019
Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohortRobert O Opoka, Heather A Hume, Teresa S Latham, et al.
The New England Journal of Medicine|December 4, 2018
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan AfricaLéon Tshilolo, George Tomlinson, Thomas N Williams, et al.
Blood|August 31, 2011
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemiaRussell E Ware, Jenny M Despotovic, Nicole A Mortier, et al.
Frontiers in Physiology|April 12, 2021
Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell AnemiaAlina Sadaf, Katie G Seu, Elizabeth Thaman, et al.
Blood|December 2, 2011
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectinJeffrey D Lebensburger, Thad Howard, Yunming Hu, et al.
American Journal of Hematology|July 18, 2013
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trialOfelia Alvarez, Nancy A Yovetich, J Paul Scott, et al.
Trials|September 22, 2023
Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC diseaseLuke R Smart, Catherine I Segbefia, Teresa S Latham, et al.
JMIR Research Protocols|June 4, 2017
Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell AnemiaNeelum D Jeste, Luisanna M Sánchez, Gabriela S Urcuyo, et al.
Journal of Pediatric Hematology/Oncology|July 26, 2018
Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell AnemiaLori E Crosby, Ashley Walton, Lisa M Shook, et al.
Blood|August 24, 2012
Impact of hydroxyurea on clinical events in the BABY HUG trialCourtney D Thornburg, Beatrice A Files, Zhaoyu Luo, et al.
Pageof 27